TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Emmaus Life Sciences Reports Quarterly Financial Results

Benzinga Logo Benzinga By Prnewswire
Emmaus Life Sciences Reports Quarterly Financial Results

Emmaus Life Sciences reported a 38% decline in net revenues for Q3 2025, attributed to generic L-Glutamine competition and lower sales in the Middle East North Africa region. The company experienced a net loss of $2.1 million and reduced operating expenses by 43%.

Insights
TBB   neutral

Used as a comparative benchmark for Verizon's valuation metrics


EMMA   negative

Experienced revenue decline, net loss, reduced cash reserves, and ongoing market competition for their primary product